75,000 Too Many: How Can States, Providers & Advocates Address and Reverse the Trend of Babies Born with Dependence on Opioids?
|
|
- Milo Jenkins
- 5 years ago
- Views:
Transcription
1 75,000 Too Many: How Can States, Providers & Advocates Address and Reverse the Trend of Babies Born with Dependence on Opioids? National Council for Behavioral Health December 14 th, 2016 Jean Y. Ko, PhD Michael D. Warren, MD MPH FAAP
2 Welcome! Margaret A. Jaco MSSW Senior Policy Associate National Council for Behavioral Health
3 Housekeeping Technical Difficulties? Call Citrix Tech Support at
4 Webinar Agenda Neonatal Abstinence Syndrome (NAS) Implications of NAS Treatment & Costs Prevention Challenges Intervention Challenges CDC work around NAS The Opioid Epidemic: A Tennessee Perspective Generating Data for Action Data Action: Local Level Data Action: State Level Q&A
5 Guest Speaker #1 Jean Y. Ko, PhD LCDR, U.S. Public Health Service Epidemiologist, CDC s Division of Reproductive Health JeanKo@cdc.gov
6 Neonatal Abstinence Syndrome Jean Ko, PhD Epidemiologist LCDR, U.S. Public Health Service Division of Reproductive Health National Center for Chronic Disease Prevention and Health Promotion 6
7 What is Neonatal Abstinence Syndrome (NAS)? Drug withdrawal syndrome that occurs primarily among opioid-exposed infants shortly after birth Withdrawal symptoms most commonly occur hours after birth Tremors, hyperactive reflexes, seizures Excessive or high-pitched crying, irritability, yawning, stuffy nose, sneezing, sleep disturbances Poor feeding and sucking, vomiting, loose stools, dehydration, poor weight gain Increased sweating, temperature instability, fever Hudak ML, Tan RC, Committee on Drugs, et al. Pediatrics. 2012;129;e
8 Exposures Associated with NAS Cocaine, amphetamines, and barbiturates have been implicated Most commonly attributed to exposure to opioids Pain relievers: Vicodin, OxyContin, Percocet Illicit substances: Heroin Opioid maintenance therapy: Methadone, buprenorphine Maintenance therapy: Long-term treatment for opioid use disorder, under medical supervision, with a longer-acting but less euphoric opioid Recommended by American College of Obstetricians and Gynecologists (ACOG) during pregnancy 8 ACOG: American College of Obstetricians and Gynecologists ACOG Committee on Health Care for Underserved Women, American Society of Addiction Medicine. Obstet Gynecol May;119(5):
9 Prescribing of Opioids to Women of Reproductive Age 50% 40% 30% 20% 10% 0% Opioid Prescription Claims by Type of Health Insurance Among Women of Reproductive Age (15-44 years), United States, % Private Insurance 39.4% Medicaid-enrolled Ailes EC, Dawson AL, Lind JN, et al. MMWR Jan 23;64(2):
10 Opioid Abuse and Dependence Among Pregnant Women Opioid abuse or dependence per 1,000 deliveries, overall and by age in the U.S., Maeda A, Bateman BT, Clancy CR, et al. Anesthesiology Dec;121(6):
11 Drug Overdose Deaths Among Women cdc.gov/vitalsigns/prescriptionpainkilleroverdoses/index.html 11
12 Incidence of NAS in the United States, Patrick SW, Schumacher RE, Benneyworth BD, et. al. JAMA. 2012;307(18): Patrick SW, Davis MM, Lehmann CU, et al. J Perinatol Aug;35(8):650-5.
13 Incidence of NAS in the United States, Patrick SW, Schumacher RE, Benneyworth BD, et. al. JAMA. 2012;307(18): Patrick SW, Davis MM, Lehmann CU, et al. J Perinatol Aug;35(8):650-5.
14 NAS Incidence by Geographic Region, 2012 NAS per 1,000 Hospital Births Patrick SW, Davis MM, Lehmann CU, et al. J Perinatol Aug;35(8):
15 Incidence of Neonatal Abstinence Syndrome 25 States, Incidence rates per 1,000 hospital births Ko JY, Patrick SW, Tong VT, Patel R, Lind JN, Barfield WD. MMWR Morb Mortal Wkly Rep 2016;65:
16 Infants with NAS: Treatment and Costs Exposed infants can require pharmacologic treatment (e.g. morphine, methadone, phenobarbital) 30%, 68%, and 91% of NAS infants required pharmacologic treatment in separate studies Mean length of hospital stay: 23 days Mean hospital charge: $93,400 per infant Total cost: $1.5 billion Medicaid is most common payer ($1.2 billion) 16 Strauss ME, Andresko M, Stryker JC, et al. Am J Obstet Gynecol Dec 1;120(7): Ebner N, Rohrmeister K, Winklbaur B, et al. Drug Alcohol Depend Mar 16;87(2-3): Patrick SW, Davis MM, Lehmann CU, et al. J Perinatol Aug;35(8): Kuschel C. Semin Fetal Neonatal Med Apr;12(2): Greig E, Ash A, Douiri A. Arch Gynecol Obstet Oct;286(4):
17 Prevention Challenges Nearly 50% of all pregnancies in the United States are unintended 86% of pregnancies are unintended among women who abuse opioids Unmet need for increased access to preconception healthcare Including effective contraception among women who do not intend to become pregnant 17 Finer LB, Zolna MR. N Engl J Med. 2016;374: Heil SH, Jones HE, Arria A, et al. J Subst Abuse Treat Mar;40(2):
18 Prevention Challenge: High Opioid Prescribing Rates Number of opioid prescriptions per 100 people cdc.gov/vitalsigns/opioid-prescribing/infographic.html cdc.gov/drugoverdose 18 cdc.gov/vitalsigns/opioid-prescribing/infographic.html cdc.gov/drugoverdose
19 Intervention Challenges Universal verbal screening for substance use recommended by ACOG but not implemented Few screening instruments validated for use among pregnant woman Debate on when and how often to screen, whether biological specimens should be used in conjunction Varying state laws and policies Unmet need for referrals and resources Standardization of care for NAS infants Assessment Treatment (first line medication, quantity) ACOG Committee on Health Care for Underserved Women, American Society of Addiction Medicine. Obstet Gynecol May;119(5):
20 CDC Recommendations: Providers for Preconception and Pregnant Women Reproductive-aged women discuss family planning and how long-term opioid use might affect any future pregnancy Pregnant women Carefully weigh risks and benefits when making decisions about whether to initiate opioid therapy Pregnant women with opioid use disorder medication-assisted therapy with buprenorphine (without naloxone) or methadone has been associated with improved maternal outcomes and should be offered Dowell D, Haegerich TM, Chou R. MMWR Recomm Rep. 2016;65(No. RR-1):
21 Prescription Drug Monitoring Programs (PDMPs) State-based databases of controlled prescription drugs dispensed by pharmacies Currently in 49 states (not Missouri) Contain critical clinical data that can help: Identify patients at risk for opioid-related overdoses On high total doses, receiving from multiple sources Inform providers of other medications the patient is receiving that may interact with those prescribed Identify patients struggling with opioid use disorder pdmpexcellence.org/sites/all/pdfs/coe_briefing_mandates_2nd_rev.pdf 21
22 CDC s Treating for Two Initiative Treating for Two: Safer Medication Use in Pregnancy initiative focuses on improving the health of women and babies and preventing birth defects and other adverse pregnancy outcomes. Expand and accelerate research to fill knowledge gaps Deliver up-to-date information to support decision making among prescribers, pharmacists, and consumers Evaluate evidence to facilitate reliable guidance 22 National Center on Birth Defects and Developmental Disabilities
23 CDC s Division of Reproductive Health Activities Improving surveillance data Pregnancy Risk Assessment Monitoring System- capabilities to capture prescription opioid use Understanding Knowledge, Attitudes, and Practices of Ob/Gyns regarding pregnant patients who use opioids Funding a study to compare and validate substance use screening tools Comparing 5 existing screening tools and their performance (sensitivity, specificity) Funding Perinatal Quality Collaboratives 23
24 Public Health Grand Rounds and Technical Assistance Primary Prevention and Public Health Strategies to Prevent Neonatal Abstinence Syndrome ( 2016/august2016.htm) Technical assistance to states to improve availability and quality of data collection and surveillance activities regarding NAS Authorized by Protecting Our Infants Act,
25 25 Questions?
26 Guest Speaker #2 Michael D. Warren, MD MPH FAAP Deputy Commissioner for Population Health Tennessee Department of Health
27 The Opioid Epidemic: A Tennessee Perspective Michael D. Warren, MD MPH FAAP Deputy Commissioner for Population Health National Council for Behavioral Health December 14, 2016
28 Objectives Describe the implementation of a real-time surveillance system for neonatal abstinence syndrome (NAS) in Tennessee Identify examples of using NAS surveillance and other data to drive state-level program, policy, and legal efforts to address neonatal abstinence syndrome in the broader context of an opioid epidemic
29 Generating Data for Action
30 Number of Hospitalizations NAS in Tennessee: NAS Hospitalizations in Tennessee, Number Rate What our partners were telling us What our state administrative data were showing us Rate per 1,000 Live Births Data sources: Tennessee Department of Health; Office of Health Statistics; Hospital Discharge Data System (HDDS) and Birth Statistical System. Analysis includes inpatient hospitalizations with age less than 1 and any diagnosis of drug withdrawal syndrome of newborn (ICD-9- CM 779.5). HDDS records may contain up to 18 diagnoses. Infants were included if any of these diagnosis fields were coded
31 NAS in Tennessee: 2012 What we knew in 2012 What we didn t know in 2012 Hospital discharge data through 2010 showed sharp increase in NAS cases 2011 or 2012 case numbers State rules re: release of hospital discharge data Feedback from hospitals (particularly in East TN): Busting at the seams with NAS babies Source of prenatal exposure Not easily identifiable via administrative claims Increase in drug overdose deaths We have a problem
32 NAS as a Reportable Disease Add NAS to state s Reportable Diseases and Events list State Health Officer (Commissioner) has authority to add conditions to list as appropriate Effective January 1, 2013 Reporting hospitals/providers submit electronic report Reporting Elements Case Information Diagnostic Information Source of Maternal Exposure
33 Number of Cases Neonatal Abstinence Syndrome Surveillance Summary Week 48: November 27 December 3, 2016 Year to Date Reporting Summary Total Cases Reported: 909 Cumulative Cases NAS Reported 2016 Cases 2015 Cases 2014 Cases 2013 Cases Sex Male 481 Maternal County of Residence Female 428 # Cases % Cases 2 Davidson East Week Hamilton Jackson/Madison Knox Mid-Cumberland North East Shelby South Central South East Sullivan Upper Cumberland West TOTAL Source of Exposure # Cases 3 % Cases Medication assisted treatment Legal prescription of an opioid pain reliever Legal prescription of a non-opioid Prescription opioid obtained without a prescription Non-opioid prescription substance obtained without a prescription Heroin Other non-prescription substance No known exposure Other Summary reports are archived weekly at: 2. Total percentage may not equal 100.0% due to rounding. 3. Multiple maternal substances may be reported; therefore the total number of cases in this table may not match the total number of cases reported. 4. Other exposure may include cases reported to the archived surveillance system with classifications not captured in the current system.
34 NAS Exposure Source, 2015 Mix of prescription and illicit substances 22.1% Substance exposure unknown 5.5% Only illicit/diverted substances 25.9% Only substances prescribed to mother 46.5% Tennessee Department of Health. Neonatal Abstinence Syndrome Surveillance System.
35 Percent, % NAS Exposure Source by Region, Unknown (%) Prescription Drugs Only (%) Prescription and Illicit Drugs (%) Illicit Drugs Only (%) Tennessee Department of Health. Neonatal Abstinence Syndrome Surveillance System.
36 Data to Action: Local Level
37 NAS Incidence, by TN Region, 2013 Month NAS Cases Births* Rate (per 1,000 births) Davidson 35 9, East 268 7, Hamilton 17 4, Jackson/Madison 2 1, Knox 102 5, Mid-Cumberland 58 14, Northeast 138 3, Shelby 24 13, South Central 29 4, Southeast 12 3, Sullivan 86 1, Upper Cumberland 117 3, West 33 5, TOTAL , *Provisional count of births, 2013
38 NAS: Levels of Prevention PRIMARY Prevention SECONDARY Prevention TERTIARY Prevention Definition An intervention implemented before there is evidence of a disease or injury An intervention implemented after a disease has begun, but before it is symptomatic. An intervention implemented after a disease or injury is established Intent Reduce or eliminate causative risk factors (risk reduction) Early identification (through screening) and treatment Prevent sequelae (stop bad things from getting worse) NAS Example Prevent addiction from occurring Prevent pregnancy Screen pregnant women for substance use during prenatal visits and refer for treatment Treat addicted women Treat babies with NAS Adapted from: Centers for Disease Control and Prevention. A Framework for Assessing the Effectiveness of Disease and Injury Prevention. MMWR. 1992; 41(RR-3); 001. Available at:
39 Narcotics/Contraceptive Use, TennCare, 2014 Demographics TennCare Women Women Prescribed Narcotics (>30 days supplied) Narcotic Users Rate per 1,000 Women Prescribed Contraceptive s and Narcotics % of Women on Narcotics and Contraceptives Women Prescribed Narcotics without Contraceptives % of Women on Narcotics Not on Contraceptives All Women 320,327 38, ,625 15% 32,585 85% ,174 1, % % ,169 2, % 1,973 71% ,165 6, ,561 22% 5,437 78% ,614 9, ,459 15% 8,024 85% ,963 9, % 8,477 91% ,241 8, % 7,882 95% Data source: Division of Health Care Finance and Administration, Bureau of TennCare. CY2014 data. Available at:
40 East TN NAS Primary Prevention Project Primary Prevention Initiative (PPI): Department-wide initiative Vision by State Health Officer Focus upstream Engage community partners to address local issues East TN PPI Project: Started in Cocke and Sevier counties Partnership with local jails Health education sessions Focus on NAS prevention Information on effective contraception Partnerships with jails to refer inmates to local health department for family planning
41 East TN NAS Primary Prevention Project All services are voluntary Any patient referred to health department for family planning services is offered a variety of acceptable and effective contraceptive methods Selected results from East TN PPI project: 442 referrals in % with history of drug use 30% reported drug use during pregnancy 19% had delivered infant with NAS 73% reported no contraceptive method Among referred patients: 94% received a contraceptive method (N=406) 84% chose a voluntary reversible long-acting contraceptive (N=361)
42 Data to Action: State Level
43 Number of Hospitalizations NAS in Tennessee: 2012 NAS Hospitalizations in Tennessee, Number Rate Rate per 1,000 Live Births Data sources: Tennessee Department of Health; Office of Health Statistics; Hospital Discharge Data System (HDDS) and Birth Statistical System. Analysis includes inpatient hospitalizations with age less than 1 and any diagnosis of drug withdrawal syndrome of newborn (ICD-9- CM 779.5). HDDS records may contain up to 18 diagnoses. Infants were included if any of these diagnosis fields were coded
44 TennCare NAS Costs, CY2011 Metric TennCare Paid Live Births 1 TennCare non-lbwt Births TennCare Live LBWT Births 2 NAS Infants Number of Births 45,205 40,437 4, Cost for Infant in first year of life $350,936,293 $171,336,964 $179,599,329 $33,249,612 Average Cost per child $7,763 $4,237 $37,668 $62,973 Average length of stay (days) % of infants 9.5% of costs Data source: Division of Health Care Finance and Administration, Bureau of TennCare. 1. This sample contains only children that were directly matched to TennCare s records based on Social Security Number. 2. Any infant weighing under 2,500g at the time of birth was considered low birth weight (LBWT).
45 Infants in DCS Custody, TennCare, CY2011 Infants born in CY 2011 NAS infants Total # of Infants 55, Total # infants in DCS % in DCS 1.4% 22.7% Data source: Division of Health Care Finance and Administration, Bureau of TennCare. This sample contains only children that were directly matched to TennCare s records based on Social Security Number.
46 NAS Subcabinet Working Group Convened in late Spring 2012 Committed to meeting every 3-4 weeks Cabinet-level representation from Departments: Public Health (TDH) Children s Services (DCS) Human Services (DHS) Mental Health and Substance Abuse Services (DMHSAS) Medicaid (TennCare) Children s Cabinet
47 Request for Black Box Warning
48
49 TennCare Prior Authorization Form Form available at:
50 Related Laws Encourages opioid antagonist prescribing for atrisk individuals Immunity for antagonist administrators Collaborative pharmacy practice agreement Priority to pregnant women for statefunded treatment Treatment as affirmative defense (sunset in 2016) Naloxone Treatment Clinic operations, medical director (pain medicine specialist), and ownership defined All must be licensed by 2017, licensure tied to medical director Prescription Drug Monitoring Program Opioid-Related Laws in Tennessee Pain Management Clinics Shall-check for most controlled substances Data reported from dispensers daily TDH Chronic Pain Management Guidelines 2-hr CME requirement Prescribing Tamper-proof prescription pads Identify/investigate top 50 prescribers and top 10 rural prescribers Dispensing 30-day limit for dispensing of opioids/benzos Limitations on direct dispensing by prescribers ID required for pickup On-site inspection every other year No cash payment (except copay) Guidelines forthcoming
51 Public Health Approach to the Opioid Abuse Epidemic Tennessee Department of Health Strategic Map, 2016 Reduce Opioid Misuse, Abuse & Overdose Adopted 1/11/16 A B C D Improve Primary Prevention Improve Monitoring and Surveillance Improve Regulation and Enforcement Increase Utilization of Treatment (2º Prevention) E Increase Access to Appropriate Pain Management 1 Improve education for consumers, families & HCWs Optimize use of the CSMD Provide prescriber/ dispenser education on regulation & enforcement Destigmatize & approach addiction as a treatable chronic illness Require pain management clinic physicians to have specialty certification 2 Expand use of optimal prescribing guidelines Link other data sources to the CSMD Improve collaboration with law enforcement Expand SBIRT training and use Develop a model for desirable integrated pain practices 3 Actively support community coalitions Improve the high risk patient model Expedite investigations supporting Board oversight of prescribers Expand appropriate use of MAT Increase access for uninsured 4 Expand efforts to reduce NAS Develop a high risk prescriber model for individuals and practices Eliminate Pill Mills Expand treatment alternatives to incarceration Work with academic partners to improve training of prescribers 5 Facilitate community interventions, including safe disposal of drugs Develop a high risk dispenser model Improve legislation to allow proactive regulation Partner with Mental Health to expand treatment options for opioid misuse Describe how patient care is impacted by sudden clinic closure 6 Reduce harm from needle use Improve proactive use of clinical monitoring tools Advocate for Prescription for Success including treatment and care Expand the availability and use of Naloxone Expand and Strengthen Key Partnerships and Collaborative Infrastructure Secure/Realign Resources and Infrastructure to Implement Comprehensive Approaches Use Data, Evaluation and Research to Inform Interventions and Continuous Improvement
52 State Policy Efforts Mandatory prescriber education Opioid Prescribing Guidelines Eliminating Pill Mills Prescription Drug Monitoring Programs Increased Access to Naloxone Availability of Opioid Use Disorder Treatment Source: National Security Council. Prescription Nation 2016: Addressing America s Drug Epidemic.
53 Process Impact: PDMP Law Tennessee Department of Health. Controlled Substance Monitoring Database Report to the 109 th General Assembly.
54 MME Outcome Impact: MME Dispensed 10,000,000,000 9,000,000,000 8,000,000,000 7,000,000,000 6,000,000,000 5,000,000,000 4,000,000,000 3,000,000,000 2,000,000,000 1,000,000,000 Opioid MMEs and Prescriptions Dispensed to TN Patients and Reported to the CSMD, * 14.3% decrease in MME from 2012 to Year MME filled by all patients in CSMD *Excluding prescriptions reported from VA pharmacies. MME filled by TN patients Tennessee Department of Health. Controlled Substance Monitoring Database.
55 Collaborative Research Projects 5 grants awarded to collaborative research partnerships Address key NAS research questions Answerable: With TN data and expertise Within one year Funded with MCH Block Grant funds and Medicaid Infant Mortality/Women s Health grant RESEARCH TOPICS Development of a predictive model for NAS Barriers to contraception in women attending substance abuse programs Optimal management of the pregnant woman taking opioids Understanding and improving provider knowledge and behavior Understanding optimal management of the infant with NAS
56 Summary Real-time surveillance for emerging issues like NAS is possible using low-cost solutions NAS surveillance in TN has allowed for more robust description of exposure sources Utilization of data from multiple sources allows for targeting of local prevention efforts as well as state programs and policies Addressing NAS and the broader opioid epidemic requires a multi-faceted, long-term approach
57 For More Information Weekly NAS Surveillance Archive Monthly and Annual NAS Reports
58 Acknowledgements TDH Commissioner John J. Dreyzehner, MD, MPH, FACOEM TDH Chief Medical Officer David R. Reagan, MD, PhD TDH NAS Surveillance Angela M. Miller, PhD, MSPH East TN Regional Health Office Staff Danni Lambert, RN Janet Ridley, RN, BSN, MSN Brittany S. Isabell, MPH
59 Comments & Questions?
60 Thank you for joining us for today s 75,000 Too Many How Can States, Providers & Advocates Address & Reverse the Trend of Babies Born with Dependence on Opioids? webinar!
Addressing the Opioid Epidemic in Tennessee
Addressing the Opioid Epidemic in Tennessee A Multidisciplinary Approach Melissa McPheeters, PhD, MPH Director, Informatics and Public Health Analytics 26 108 733 *Source: CDC References Centers for
More informationMaternal Substance Abuse: Challenges & Opportunities for Perinatal Nurses Catherine H. Ivory, PhD, RNC-OB October, 2015
Maternal Substance Abuse: Challenges & Opportunities for Perinatal Nurses Catherine H. Ivory, PhD, RNC-OB October, 2015 Objectives Discuss the current scope of maternal substance use and abuse List examples
More informationMarch 20 th, Public Health Approaches to Addressing Neonatal Abstinence Syndrome
March 20 th, 2018 Public Health Approaches to Addressing Neonatal Abstinence Syndrome Technical Tips Audio is broadcast through computer speakers Download resources in the File Share pod (above the slides)
More informationMental and Behavioral Health
Mental and Behavioral Health Mental Health Poor mental health is a major source of distress, disability, and social burden. In any given year, as many as one in five adults in the United States have a
More informationASTHO President s Challenge 15 x 15: Reduce Prescription Drug
ASTHO President s Challenge 15 x 15: Reduce Prescription Drug Misuse and Deaths 15% by 2015 Terry Cline, Ph.D. Commissioner of Health Oklahoma Secretary of Health and Human Services Prescription drugs
More informationLearning Objectives. Serving Pregnant Women Affected by Substance Use Disorders in Healing to Wellness Court: Sharing Lessons
Serving Pregnant Women Affected by Substance Use Disorders in Healing to Wellness Court: Sharing Lessons Marianna Corona Jennifer Foley September 12, 2017 Learning Objectives 2017 Improving Family Outcomes
More information4/19/2018. Opioid Use Disorder in Pregnancy OBJECTIVES ANTENATAL TESTING
Opioid Use Disorder in Pregnancy 2017 Recommendations from ACOG and The Pew Charitable Trust KATHY D. HARTKE, MD, LEGISLATIVE CO-CHAIR AND IMMEDIATE PAST CHAIR, WISCONSIN SECTION OF THE AMERICAN COLLEGE
More informationNEONATAL ABSTINENCE SYNDROME. NAS Kickoff 11/8/18
NEONATAL ABSTINENCE SYNDROME NAS Kickoff 11/8/18 OPIOID EPIDEMIC STATISTICS USA is 4.6% of the world s population 78 Americans die every day from opioid overdoses 66% of all illegal drug use 80% of global
More informationMaternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC
Maternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC Objectives 1. Discuss the effects of opiate addiction on mothers and infants. 2. Discuss a Medical Home
More informationClinical Management of Neonatal Abstinence Syndrome. Tricia L. Romesberg, DNP, MSN, ARNP, CNNP
Clinical Management of Neonatal Abstinence Syndrome Tricia L. Romesberg, DNP, MSN, ARNP, CNNP Timeline Incidence of NAS Healthcare Cost and Utilization Project (HCUP), 1999-2013 State Inpatient Databases
More informationE. Omohundro, PhD, 3/15/2017 Office of Research 2
Ellen Omohundro, PhD, 3/15/217 Successes Both the number of prescriptions and quantity of opioids prescribed are decreasing. Challenges Opioid crimes, especially heroin crimes, are on the rise. Injection
More informationEmergent Issues Affecting Early Intervention/ Early Childhood. Workforce Development for Inclusion in Early Childhood November 4, 2017 Washington, DC
Emergent Issues Affecting Early Intervention/ Early Childhood Workforce Development for Inclusion in Early Childhood November 4, 2017 Washington, DC Conversation Points Changing Demographics Emergent Trends
More informationOpioid Use in Pregnant Women and Prenatal Care. Murray F Dweck MD, FACOG Medical Director/OBGYN Florida Department of Health -Brevard
Opioid Use in Pregnant Women and Prenatal Care Murray F Dweck MD, FACOG Medical Director/OBGYN Florida Department of Health -Brevard Objectives Summarize contextual and co-morbid factors observed among
More informationObjectives. Care of the Neonate with Prenatal Opioid Exposure. What is Neonatal Abstinence Syndrome (NAS)? Increasing Incidence of NAS 8/27/2016
Care of the Neonate with Prenatal Opioid Exposure Heather Pratt Chavez, MD Ann Winegardner, MD Objectives Review the latest population data on neonates with prenatal opioid exposure Describe the acute
More informationOpioid Use Disorder in Pregnancy. Neonatal Abstinence Syndrome
Opioid Use Disorder in Pregnancy Neonatal Abstinence Syndrome Opioid Use Disorder and Pregnancy Cont. 4.6 million women (or 3.8 percent) ages 18 and older misused prescription drugs in 2013. One-third
More informationADDRESSING THE OPIOID EPIDEMIC. Joint principles of the following organizations representing front-line physicians
ADDRESSING THE OPIOID EPIDEMIC Joint principles of the following organizations representing front-line physicians American Academy of Family Physicians American Academy of Pediatrics American College of
More informationPerformance of North Carolina's System for Monitoring Prescription Drug Abuse. Session Law , Section 12F.16.(q)
Performance of North Carolina's System for Monitoring Prescription Drug Abuse Session Law 2015-241, Section 12F.16.(q) Report to the Joint Legislative Oversight Committee on Health and Human Services and
More informationWhite Paper on. Prescription Drug Abuse
White Paper on Prescription Drug Abuse October 22, 2014 Table of Contents: I. Introduction II. Scope of the Problem III. Most Common Drugs Involved in Overdoses IV. Efforts in Tennessee V. Prescription
More informationTrends and Challenges: The Kentucky Opioid Crisis. Jason Smith, MD PhD University of Louisville
Trends and Challenges: The Kentucky Opioid Crisis Jason Smith, MD PhD University of Louisville Brief Introduction I am by no means an expert I have no financial disclosures Jokes are meant to be lighthearted
More informationAssociation of State and Territorial Health Officials (ASTHO)
Association of State and Territorial Health Officials (ASTHO) Strategy Session on Prescription Drug Misuse and Abuse Prepared by: August 13-14, 2013 Table of Contents Introduction... 1 Setting Future Direction
More informationSuccessful Prevention Strategies to Address the Opioid Crises
Successful Prevention Strategies to Address the Opioid Crises Shannon Breitzman, MSW, Principal Denver Office Lindsey Kato, MPH, CHES, Consultant Denver Office 1 LEARNING OBJECTIVES + Find out how to effectively
More informationOpioid Use Disorders and Pregnancy. Marcela Smid, MD Maternal-Fetal Medicine
Opioid Use Disorders and Pregnancy Marcela Smid, MD Maternal-Fetal Medicine UNIVERSITY OF UTAH HEALTH, 2017 OBJECTIVES Definitions Epidemiology Pharmacology Effects on pregnancy Screening Treatment CARE
More informationMaternal and Child Health, Substance Abuse Ohio Department of Health, Bureau of Maternal Child and Family Health
Maternal and Child Health, Substance Abuse Ohio Department of Health, Bureau of Maternal Child and Family Health Columbus, Ohio Assignment Description The rapid advance of the opiate crisis has had far
More informationNeonatal Abstinence Syndrome and Maternal Substance Abuse in Tennessee
Neonatal Abstinence Syndrome and Maternal Substance Abuse in Tennessee 1999-2011 Tennessee Department of Health Division of Policy, Planning and Assessment Surveillance, Epidemiology and Evaluation TENESSEE
More informationPROJECT DOVE. Improving Maternal and Neonatal Health Through Safer Opioid Prescribing
PROJECT DOVE Improving Maternal and Neonatal Health Through Safer Opioid Prescribing PARTNERS SUPPORT Bureau of Justice Assistance, Department of Justice Rhode Island Opportunity Non-medical prescription
More informationScience = Solutions For Substance Use Disorders and Infant Outcomes. Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse
Science = Solutions For Substance Use Disorders and Infant Outcomes Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse Science = Solutions Increased Opioid Mortality: Greater
More informationCare of the Neonate with Prenatal Opioid Exposure. Objectives. What is Neonatal Abstinence Syndrome (NAS)/ Neonatal Opiate Withdrawal Syndrome?
Care of the Neonate with Prenatal Opioid Exposure Heather Pratt Chavez, MD Ann Winegardner, MD Objectives Review the latest population data on neonates with prenatal opioid exposure Describe the acute
More informationImplementing the 2017 President s Challenge: Primary, Secondary & Tertiary Prevention of Addiction & Substance Misuse
Implementing the 2017 President s Challenge: Primary, Secondary & Tertiary Prevention of Addiction & Substance Misuse Jay Butler, MD, President of ASTHO, Chief Medical Officer, Alaska Department of Health
More informationGovernor Raimondo s Task Force on Overdose Prevention and Intervention May 9, 2018
Governor Raimondo s Task Force on Overdose Prevention and Intervention May 9, 2018 DIRECTOR NICOLE ALEXANDER-SCOTT, MD, MPH, RHODE ISLAND DEPARTMENT OF HEALTH DIRECTOR REBECCA BOSS, MA, RHODE ISLAND DEPARTMENT
More informationOpioid Prescribing Improvement Program
Opioid Prescribing Improvement Program Jeff Schiff, MD, MBA, Medical Director of Minnesota Health Care Programs Sarah Rinn, MPH, Opioid Prescribing Improvement Program Coordinator Agenda Opioid Prescribing
More informationHHS Priorities and Actions to Support Treatment for Those with Opioid Use Disorder
HHS Priorities and Actions to Support Treatment for Those with Opioid Use Disorder Brett Giroir, U.S. Department of Health and Human Services Join the conversation at #OUDTreatment #EndTheStigma Expanding
More informationNeonatal Abstinence Syndrome Epidemiology, diagnosis, management and prevention
Neonatal Abstinence Syndrome Epidemiology, diagnosis, management and prevention Cynthia Thomas, DO,MPH Northeast Regional Health Office Tennessee Department of Health Disclosure Statement of Financial
More informationSeptember 1, The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201
September 1, 2017 The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201 Dear Secretary Price: The National Association of County
More informationProduct Labeling to Communicate Benefits and Risks of Treatment for Opioid Use Disorder in Pregnant Women. Hendrée E. Jones, PhD
1 The National Academies of Sciences, Engineering and Medicine Regulatory Strategies of address prescription opioidrelated harms 4 th of November, 2016 Washington DC Product Labeling to Communicate Benefits
More informationBuilding a Comprehensive, Community-driven Prevention Approach to the Opioid Crisis in Maine
Building a Comprehensive, Community-driven Prevention Approach to the Opioid Crisis in Maine Scott M. Gagnon, MPP, PS-C Director, AdCare Educational Institute of Maine, Inc. Co-Chair, Prevention & Harm
More informationProtecting Children s Safety: How Prescription Drug Monitoring Programs Can Assist An Update Presenter: John L. Eadie Moderator: Cindy Rodgers
Protecting Children s Safety: How Prescription Drug Monitoring Programs Can Assist An Update Presenter: John L. Eadie Moderator: Cindy Rodgers Audio is streaming through your computer speakers. If you
More informationOpioid Data for Local Governments in North Carolina
Opioid Data for Local Governments in North Carolina Mary Beth Cox, Stacy Taylor, and Adam Lovelady October 10, 2018 Speakers Adam Lovelady Associate Professor UNC School of Government Mary Beth Cox Substance
More informationOverdose Prevention and Intervention Task Force January 10, 2018
Overdose Prevention and Intervention Task Force January 10, 2018 CO-CHAIRS: DIRECTOR NICOLE ALEXANDER-SCOTT, MD, MPH, RHODE ISLAND DEPARTMENT OF HEALTH DIRECTOR REBECCA BOSS, MA, RHODE ISLAND DEPARTMENT
More informationMAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids
MAT IN PREGNANCY R. COREY WALLER MD, MS PRINCIPAL, HEALTH MANAGEMENT ASSOCIATES FACULTY, INSTITUTE FOR HEALTHCARE INNOVATION (IHI) CHAIR, LEGISLATIVE ADVOCACY COMMITTEE, ASAM KAYLA LIFE STAGE 1: ADOLESCENCE
More informationImproving care for pregnant people with opioid use disorder in U.S. jails: Research to implement medication assisted treatment
Improving care for pregnant people with opioid use disorder in U.S. jails: Research to implement medication assisted treatment Carolyn Sufrin, MD, PhD Departments of Gyn/Ob and Health, Behavior & Society
More informationOpioid Abuse and Prescribing. Dr. Mitchell Mutter Director of Special Projects
Opioid Abuse and Prescribing Dr. Mitchell Mutter Director of Special Projects Auburn University February 22, 2019 Disclosure Statement of Financial Interest I, Mitchell Mutter, DO NOT have a financial
More informationThe Opioid Epidemic and PerformRx s Approach to Address It: A Collaborative Model with PBM, Payor and Behavioral Health
The Opioid Epidemic and PerformRx s Approach to Address It: A Collaborative Model with PBM, Payor and Behavioral Health Andrea Gelzer, M.D., M.S., FACP Senior Vice President and Corporate Chief Medical
More information... Health. Department of. Prenatal Drug Exposure and Neonatal Abstinence Syndrome in Northeast TN. Overview and Regional Snapshot
Department of... Health Prenatal Drug Exposure and Neonatal Abstinence Syndrome in Northeast TN Overview and Regional Snapshot Cynthia C. Thomas, DO, MPH, Assistant Health Officer, Northeast Regional Health
More informationFrom Medicaid Transformation Approved Project Toolkit, June 2017
From Medicaid Transformation Approved Project Toolkit, June 2017 Domain 3: Prevention and Health Promotion Transformation projects within this domain focus on prevention and health promotion to eliminate
More informationPresented by DCF SunCoast Region: Kyle Teague, Melissa Worthen, Christina Cuoco, Nina Romeu, Dekesha Seay
Presented by DCF SunCoast Region: Kyle Teague, Melissa Worthen, Christina Cuoco, Nina Romeu, Dekesha Seay Overview/Learning Objectives What is Addiction Medication Assisted Treatment Discuss facts about
More informationPrescription Opioid Overdose in Oregon: A public health perspective
Prescription Opioid Overdose in Oregon: A public health perspective Katrina Hedberg, MD, MPH Health Officer & State Epidemiologist Oregon Public Health Division Oregon Health Authority All-Cause Mortality,
More informationThe Opioid Epidemic: The State of the State
JOINT LEGISLATIVE COMMITTEE ON HEALTH AND HUMAN SERVICES The Opioid Epidemic: The State of the State Dr. Mandy Cohen, Dr. Susan Kansagra Department of Health and Human Services Nov. 14, 2017 3 PEOPLE DIE
More informationOpioid use in pregnancy and Neonatal Abstinence Syndrome
Opioid use in pregnancy and Neonatal Abstinence Syndrome Morissa Ladinsky, MD Assoc. Professor of Pediatrics Division of General Pediatrics and Adolescent Medicine UAB Objectives 1. Understand the magnitude,
More informationDHHS Vision & Priorities for the Future. M3 Conference NC Medical Society September 15, 2017
DHHS Vision & Priorities for the Future M3 Conference NC Medical Society September 15, 2017 EXPENDITURE AS % OF GDP Buying Health: Health & Social Services Expenditure by Country 50 45 40 35 30 25 20 15
More informationArizona State Office of Rural Health Webinar Series
Arizona State Office of Rural Health Webinar Series Mute your phone &/or computer microphone Time is reserved at the end for Q&A Please fill out the post-webinar survey Webinar is being recorded Recording
More informationTri-County Region Opioid Trends Clackamas, Multnomah, and Washington, Oregon. Executive Summary
Tri-County Region Opioid Trends Clackamas, Multnomah, and Washington, Oregon 2016 Executive Summary 20.8 million people in the United States have a substance use disorder (not limited to opioids), equivalent
More informationThe Impact of Neonatal Abstinence Syndrome: The View from a Rural Kentucky Hospital
Volume 3 Issue 3 Article 10 2017 The Impact of Neonatal Abstinence Syndrome: The View from a Rural Kentucky Hospital Sydni Fazenbaker Crowell, Allison M. Crump-Rogers, William Crump, and LeAnn Langston
More informationOpioid Use and Other Trends
Opioid Use and Other Trends National Overview Across the nation communities are struggling with a devastating increase in the number of people misusing opioid drugs, leading many to identify the current
More informationACCG Mental Health Summit
ACCG Mental Health Summit Sheila Pierce, Opioid Program Coordinator Director, Prescription Drug Management Program Discussion 1. Overview Opioid Problem in GA - Video 2. DPH Opioid Program 3. Priorities
More informationNEONATAL ABSTINENCE SYNDROME (NAS) AKA NEWBORN DRUG WITHDRAWAL:THE NEWARK EXPERIENCE
NEONATAL ABSTINENCE SYNDROME (NAS) AKA NEWBORN DRUG WITHDRAWAL:THE NEWARK EXPERIENCE Salma Ali MD, Debra Brendel RN, BSN, MSN and Ona Fofah MD Division of Neonatology and Newborn Medicine Department of
More informationEffects of Prenatal Illicit Drug. Use on Infant and Child
Effects of Prenatal Illicit Drug Use on Infant and Child Development Andrew Hsi, MD, MPH Larry Leeman, MD, MPH Family Medicine MCH Grand Rounds 6 July 2011 Objectives for Presentation At the end of this
More informationPRESCRIPTION DRUG ABUSE: THE NATIONAL PERSPECTIVE
PRESCRIPTION DRUG ABUSE: THE NATIONAL PERSPECTIVE September 20, 2013 Association of State and Territorial Health Officials Annual Meeting R. Gil Kerlikowske Director of National Drug Control Policy National
More informationJust Out of Reach: Women Who Use Drugs, Stigma and Barriers to Care Erin Bortel and Lyla Hunt AIDS Institute Office of Drug User Health
Just Out of Reach: Women Who Use Drugs, Stigma and Barriers to Care Erin Bortel and Lyla Hunt AIDS Institute Office of Drug User Health March 12, 2018 Envisioning a socially just system where all New Yorkers
More informationSEPA Regional Overdose Prevention Coalition. Breaking Down Silos
SEPA Regional Overdose Prevention Coalition Breaking Down Silos David A. McKeighan Executive Director Chester & Delaware County Medical Societies Chester County Overdose Task Force Delaware County Heroin
More informationDPH Priorities and Statewide Initiatives
DPH Priorities and Statewide Initiatives School and Community Health Leadership Conference/ Sara Kroening/ November 7, 2018 Georgia Public Health 159 County Boards of Health 18 Public Health Districts
More informationOpioid Overdose in Oregon Report to the Legislature
SEPTEMBER 2018 Opioid Overdose in Oregon Report to the Legislature This report summarizes the burden of opioid overdose among Oregonians as required by ORS 432.141. It describes Oregon s progress in reducing
More informationMANAGING THE COSTS OF THE OPIOID EPIDEMIC IN WISCONSIN. State Senator Alberta Darling
MANAGING THE COSTS OF THE OPIOID EPIDEMIC IN WISCONSIN State Senator Alberta Darling A NATIONAL PROBLEM According to the 2014 National Survey on Drug Use and Health: 435,000 Americans have used heroin
More informationThe Challenge of Treating Pain
FDA Charge to the Committee: FDA Opioid Action Plan and Incorporating the Broader Public Health Impact into the Formal Risk-Benefit Assessment for Opioids Robert M. Califf, MD Commissioner of Food and
More informationThe Long-Term Outcomes of Infants with Neonatal Abstinence Syndrome
Neonatal Nursing Education Brief: The Long-Term Outcomes of Infants with Neonatal Abstinence Syndrome https://www.seattlechildrens.org/healthcareprofessionals/education/continuing-medical-nursing-education/neonatalnursing-education-briefs/
More informationTHA Medication Safety Summit. Wesley Geminn, PharmD, BCPP
THA Medication Safety Summit Wesley Geminn, PharmD, BCPP Current Trends: Overdose Deaths in 2017 72,000 Or 197 per day 8 per hour National Opioid Overdose Statistics https://www.drugabuse.gov/related-topics/trendsstatistics/overdose-death-rates
More informationThe Role of Opioid Overdoses in Confirmed Maternal Deaths,
The Role of Opioid Overdoses in Confirmed Maternal Deaths, 2012-2015 Introduction The Department of State Health Services (DSHS) conducted an analysis of maternal deaths resulting from drug overdoses from
More informationNeonatal Abstinence Syndrome Questions & Answers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012)
Neonatal bstinence Syndrome Questions & nswers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012) For more information and to download a copy of the NS Clinical Practice Guidelines, please visit
More informationU.S. Counties Vulnerability to Rapid Dissemination of HIV/HCV Infections Among People Who Inject Drugs
U.S. Counties Vulnerability to Rapid Dissemination of HIV/HCV Infections Among People Who Inject Drugs Michelle Van Handel, MPH Health Scientist National Center for HIV/AIDS, Viral Hepatitis, STDs and
More informationAssessing Opioid Misuse and Overdose Using Prescription Drug Monitoring Programs (PDMP) and Other Data Sources
Assessing Opioid Misuse and Overdose Using Prescription Drug Monitoring Programs (PDMP) and Other Data Sources NPN Conference Anaheim, CA September 12, 2017 Presentations Overview of SAMHSA s Prevention
More informationNeonatal Abstinence Syndrome:
Neonatal Abstinence Syndrome: Rethinking Our Approach Matthew Grossman, M.D. Assistant Professor of Pediatrics Yale School of Medicine Quality and Safety Officer Yale-New Haven Children s Hospital Patrick,
More informationPotential Solutions to Epidemic Substance Abuse in US and Europe
Potential Solutions to Epidemic Substance Abuse in US and Europe Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center, Denver Health 1 Professor, University of Colorado School of Medicine
More informationMOMS Project Panel Overview
MOMS Project Panel Overview Rick Massatti, PhD, Ohio Department of Mental Health and Addiction Services Jennifer Bailit, MD, MetroHealth Medical Center Mike Marcotte, MD, Tri-Health Mona Prasad, DO,MPH,
More informationOpioid Epidemic as it Relates to Counties
89 TH ANNUAL WEST TEXAS COUNTY JUDGES AND COMMISSIONERS ASSOCIATION CONFERENCE Wednesday, April 25, 2018 11:05 11:55 a.m. Opioid Epidemic as it Relates to Counties Ms. Jessica Cance Agency Analytics Unit
More informationProgress Report and 2018 Legislative Opportunities. Maine Opiate Collaborative Recommendations
Progress Report and 2018 Legislative Opportunities related to the Maine Opiate Collaborative Recommendations April 2018 A. Destigmatize substance use disorders within the law enforcement profession 1.
More informationConsequences and Treatment of Opioid Abuse During Pregnancy. Katie Ellis, PharmD March 12, 2018
Consequences and Treatment of Opioid Abuse During Pregnancy Katie Ellis, PharmD March 12, 2018 Disclosure I have nothing to disclose. Objectives At the completion of this activity, the pharmacist will
More informationCentral Appalachia: A Regional Response to an Opioid Epidemic in Pregnancy
Centers for Disease Control and Prevention Central Appalachia: A Regional Response to an Opioid Epidemic in Pregnancy Jenna Meyer MPH, RNC-MNN, IBCLC Public Health Advisor Therapies for Opioid Dependent
More informationEXECUTIVE ORDER TAKING FURTHER ACTIONS TO ADDRESS THE OPIOID OVERDOSE CRISIS
EXECUTIVE ORDER TAKING FURTHER ACTIONS TO ADDRESS THE OPIOID OVERDOSE CRISIS Gina M. Raimondo, Governor Nicole Alexander-Scott, MD, MPH, Director of Health Action Plan Strategies to Date Since 2015, we
More informationKentucky s Strategic Action Plan. Katherine Marks, Ph.D. August 16, 2018
Kentucky s Strategic Action Plan Katherine Marks, Ph.D. August 16, 2018 OUTLINE The state & the need The organization of a response The action plan THE STATE AND THE NEED KENTUCKY 4.4 million people 35
More informationBERNALILLO COUNTY OPIOID ABUSE ACCOUNTABILITY SUMMIT Turning the Curve on Opioid Abuse in Bernalillo County
BERNALILLO COUNTY OPIOID ABUSE ACCOUNTABILITY SUMMIT Turning the Curve on Opioid Abuse in Bernalillo County NMPHA Annual Conference April 2, 2014 Marsha McMurray-Avila Coordinator, Bernalillo County Community
More informationINTRODUCTION. Baltimore, Maryland 6 School of Medicine West Virginia University, Morgantown, West Virginia
The American Journal on Addictions, 27: 92 96, 2018 Copyright 2018 American Academy of Addiction Psychiatry ISSN: 1055-0496 print / 1521-0391 online DOI: 10.1111/ajad.12687 Brief Report: Treating Women
More informationNAS / NOWS: Description. Disclosures: I will discuss off-label uses of medications I have no financial disclosures. Objectives
Opioid-exposed Newborns and Their Families the Vermont Approach Anne Johnston, MD Neonatal Perinatal Medicine Associate Professor of Pediatrics University of Vermont Disclosures: I will discuss off-label
More informationMay 25, Drug Overdose Update & Response: Combatting Opioid Overdose
May 25, 2017 Drug Overdose Update & Response: Combatting Opioid Overdose Overview The Problem -Overdose in North Carolina (and a little nationally) -Other associated health threats PDAAC-NC s Response
More informationOpioid Overview Admiral Brett P. Giroir, M.D.
A S S I S TA N T S E C R E TA RY F O R H E A LT H Opioid Overview Admiral Brett P. Giroir, M.D. Assistant Secretary for Health Senior Advisor for Opioid Policy @HHS_ASH August 20, 2018 SUBSTANCE ABUSE
More informationHarold Rogers Update Melissa McPheeters, PhD, MPH
Harold Rogers Update 2017 Melissa McPheeters, PhD, MPH We Need a New Normal Full collaboration among diverse departments Appropriate integration of data from disparate data sources Business intelligence
More informationHEALthy Brain and Child Development (HBCD) Study. Technical Assistance Webinar February 6, 2019
HEALthy Brain and Child Development (HBCD) Study Technical Assistance Webinar February 6, 2019 Agenda Time Topic Presenter 1:00-1:05 Opening Remarks, Introduction of NIDA & CSR Staff Gaya Dowling, NIDA
More informationNeonatal Abstinence Syndrome
Neonatal Abstinence Syndrome TAMARA HARVANKO RN, BAN HIGH RISK OB CARE COORDINATOR CASE MANAGEMENT HENNEPIN COUNTY MEDICAL CENTER TAMARA.HARVANKO@HCMED.ORG 612-873-6552 https://www.youtube.com/watch?v=tk2hoyupkvi
More informationTennCare s Opioid Strategy
TennCare s Opioid Strategy Benjamin S. Heavrin, MD, MBA, FACEP Associate Medical Director State of Tennessee Division of TennCare Rural Health Association of Tennessee 24 th Annual Conference November
More informationOPIOIDS IN JACKSON COUNTY A PUBLIC HEALTH PERSPECTIVE OPIOID AWARENESS COUNTY LEADERSHIP FORUM SHELLEY CARRAWAY, HEALTH DIRECTOR DATE
OPIOIDS IN JACKSON COUNTY A PUBLIC HEALTH PERSPECTIVE OPIOID AWARENESS COUNTY LEADERSHIP FORUM SHELLEY CARRAWAY, HEALTH DIRECTOR DATE LOCAL HEALTH DIRECTOR REGIONS For counties with low counts, regional
More informationStatus of Opioid Treatment Efforts
Status of Opioid Treatment Efforts Health Reform Oversight Committee October 25, 2016 Harry Chen, MD, Commissioner The National Safety Council Categorized Vermont as One of Four States Making Progress
More informationCDC s Efforts to End the Opioid Epidemic
Amy Insert Peeples, CIO Name MPA Here Deputy Director, National Center for Injury Prevention and Control NCSL Opioid Policy Fellows Kick Off CDC s Efforts to End the Opioid Epidemic The Epidemic in America
More informationLori A. Shook, MD Division of Neonatology Kentucky Children s Hospital University of Kentucky Medical Center
Lori A. Shook, MD Division of Neonatology Kentucky Children s Hospital University of Kentucky Medical Center NSDUH, 2012 National Survey on Drug Use and Health: 2012 Substance abuse: Public Health Problem
More informationAddressing the Opioid Crisis Workgroup: Treatment and Overdose Prevention
The Accountable Community for Health of King County Addressing the Opioid Crisis Workgroup: Treatment and Overdose Prevention May 7, 2018 1 Opiate Treatment & Overdose Prevention Project Goal Immediate:
More informationVIRGINIA S OPIOID & HEROIN OVERDOSE EPIDEMIC
1 VIRGINIA S OPIOID & HEROIN OVERDOSE EPIDEMIC Virginia Association of Counties November 14, 2016 The Honorable William A. Hazel, Jr., M.D. Secretary of Health and Human Resources 1999 - Estimated drug
More informationOpioid Abuse Treatment in Pregnancy
University of Vermont ScholarWorks @ UVM Family Medicine Block Clerkship, Student Projects College of Medicine 2015 Opioid Abuse Treatment in Pregnancy Catherine A. Suppan Follow this and additional works
More informationOctober 20, 2016 Scott K. Proescholdbell, MPH. Opioid Overdose and North Carolina s Public Health and Prevention Strategies
October 20, 2016 Scott K. Proescholdbell, MPH Opioid Overdose and North Carolina s Public Health and Prevention Strategies Deaths per 100,000 population Death Rates* for Three Selected Causes of Injury,
More informationSubmitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis
STATEMENT FOR THE RECORD Submitted to the House Energy and Commerce Committee Federal Efforts to Combat the Opioid Crisis October 25, 2017 America s Health Insurance Plans 601 Pennsylvania Avenue, NW Suite
More informationTREATING OPIOID ADDICTION IN HOMELESS POPULATIONS
TREATING OPIOID ADDICTION IN HOMELESS POPULATIONS Challenges and Opportunities Providing Medication Assisted Treatment (Buprenorphine) August 18, 2016 SPEAKERS TODAY Nilesh Kalyanaraman, MD, Chief Health
More informationTN Breastfeeding Updates. Celebrating Successes, Addressing Opportunities
TN Breastfeeding Updates Celebrating Successes, Addressing Opportunities Morgan McDonald, MD - Assistant Commissioner May 4, 2018 Objectives Emphasize critical component of breastfeeding to population
More informationMaine s Response to the Opiate Crisis. Christopher Pezzullo, DO State Health Officer Maine DHHS Maine CDC November 12, 2016
Maine s Response to the Opiate Crisis Christopher Pezzullo, DO State Health Officer Maine DHHS Maine CDC November 12, 2016 Required Disclosure Text Font typically Times New Roman at least 20 point Try
More informationRegional Opioid Safety Coalitions: Bringing communities together to prevent overdose deaths. November 3, 2015 Webinar
Regional Opioid Safety Coalitions: Bringing communities together to prevent overdose deaths November 3, 2015 Webinar Agenda Welcome, housekeeping Vision and goals Map of Coalitions Coalition member expectations
More information